In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin
about
Biology of Pseudomonas stutzeriAntibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibiotics.Advances in DNA gyrase inhibitors.Anti-anaerobic activity of antibacterial agents.Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteriaPharmacokinetics of gatifloxacin in infants and childrenMechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibioticIntegrating fluoroquinolones into the hospital formulary.Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome.Fluoroquinolones and tuberculosis.Emerging therapeutic targets in tuberculosis: post-genomic era.Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.Recent developments in the treatment of tuberculosis.Effect of gatifloxacin against Mycoplasma genitalium-related urethritis: an open clinical trial.Comparison of Drug Concentrations in Human Aqueous Humor after the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin Ophthalmic SolutionsEmerging therapies for the treatment and prevention of otitis media.Levofloxacin for the treatment of community-acquired pneumonia.The membrane as a target for controlling hypervirulent Clostridium difficile infections.Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.Antibiotic susceptibility patterns and prevalence of group B Streptococcus isolated from pregnant women in Misiones, Argentina.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps.Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species.Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones.The antibacterial agent, moxifloxacin inhibits virulence factors of Candida albicans through multitargeting.Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.Molecular characterization of 8-methoxyfluoroquinolone resistance in a clinical isolate of methicillin-resistant Staphylococcus aureus.Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.Correlation between synthesis variation of 2-alkylquinolones and the antifungal activity of a Burkholderia cepacia strain collection.Effect of ensure on the oral bioavailability of gatifloxacin in healthy volunteers.
P2860
Q24549253-BC01D697-1FB5-4797-954A-6DE9FB6B7EBBQ28344944-BB4C8717-BE7C-40BA-A89B-C0E2E9BA4FB9Q31115498-A83530B2-93FC-4DC3-9550-A3784B13427FQ31935738-A50532A7-930A-4E96-ACD3-811BF6CA7E56Q31936097-2150F113-AC12-4905-A69C-05646D9C43FBQ33805682-74184377-12A6-460E-8A3A-DBA063A8188BQ33826405-35AD45CE-CFF2-4A2F-B789-7CCDA1AC3FE2Q33856763-3E836A4B-5459-48E6-ADBE-2FFAE8269946Q33983092-FB5CD96F-3CA8-4F29-BE21-1F50850E3BD0Q34113133-F77E7526-F165-4FD6-88C6-44E208EB5E8FQ34408454-E931407D-CEB9-4B61-8DC0-FE638EDD2855Q34434848-3B491871-72E3-43EF-A299-652BE6EDB03CQ34519143-54547C5A-3DAF-4899-B51E-A4936C0DFA8BQ34568947-771B4F1D-FA01-4674-A103-A84A6190D467Q35065890-1B3A02A6-7BF9-437A-A760-46E4404868B4Q35139691-CDD42247-2F4D-45BA-965E-280651EC4FA1Q35185753-4D5848AD-3458-4304-9DB4-8937868E33C1Q35656598-4CFC51F2-A978-4762-850A-0F299F3DC124Q35739777-E690943B-5C6C-4A85-895E-1E57D4E76647Q36458405-99382FF1-5CB8-4341-A2B4-1426951BCAF3Q36670872-F9E239BB-38D7-4CC0-82C9-ED0D95A35591Q36963920-49C5BD60-1E6C-4E83-BFDA-5D63AD05AE51Q37124090-7F89E834-7280-445C-96BF-BC704161D3B5Q37159137-DB5BD574-8DA7-4865-893D-85B04BC9C536Q37346929-9A1A1CA9-7B01-4217-9AF8-B3F1407E2811Q37869167-61005A27-D122-44BA-9EE8-FFB0D8748735Q39313883-7E4DA318-FBDF-4EBE-B051-3162F01E4BA4Q39478915-BF8B78E6-783D-481D-9ED3-8CC5D11220F4Q39651507-5F4A57D6-C99A-4D87-9E48-75DCF05234D4Q40250981-D7897F2D-B1B8-4F8F-860E-52A3D9669B9AQ40469459-C1D7C2DE-778F-4D8F-82C9-C0D9A8E829CEQ41269280-66B6254A-EBCE-4E62-9234-0E5DAEFEA8F0Q44151739-AAB370F8-4BD1-49BF-8C70-56AC73E551AFQ44846722-BD30A41A-16D7-4319-AB59-3A00C5B0D5CDQ45137197-B205EC5D-D7E5-4754-AA72-2F03580E7426Q45137202-CCAD00A6-AF0C-4ACA-A324-84E6E3DDA9A5Q46157938-14D0DB24-026C-4863-B46A-4229334FB377Q46758774-A90B2C83-998D-470A-89C6-22343E53C614
P2860
In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vitro antibacterial spectru ...... fluoroquinolone, gatifloxacin
@ast
In vitro antibacterial spectru ...... fluoroquinolone, gatifloxacin
@en
In vitro antibacterial spectru ...... fluoroquinolone, gatifloxacin
@nl
type
label
In vitro antibacterial spectru ...... fluoroquinolone, gatifloxacin
@ast
In vitro antibacterial spectru ...... fluoroquinolone, gatifloxacin
@en
In vitro antibacterial spectru ...... fluoroquinolone, gatifloxacin
@nl
prefLabel
In vitro antibacterial spectru ...... fluoroquinolone, gatifloxacin
@ast
In vitro antibacterial spectru ...... fluoroquinolone, gatifloxacin
@en
In vitro antibacterial spectru ...... fluoroquinolone, gatifloxacin
@nl
P2093
P356
P1476
In vitro antibacterial spectru ...... fluoroquinolone, gatifloxacin
@en
P2093
P304
P356
10.1093/JAC/45.4.437
P407
P577
2000-04-01T00:00:00Z